A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease

DSpace/Manakin Repository

A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease

Citable link to this page

 

 
Title: A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease
Author: Rosas, Herminia D; Doros, Gheorghe; Bhasin, Swati; Thomas, Beena; Gevorkian, Sona; Malarick, Keith; Matson, Wayne; Hersch, Steven M

Note: Order does not necessarily reflect citation order of authors.

Citation: Rosas, Herminia D, Gheorghe Doros, Swati Bhasin, Beena Thomas, Sona Gevorkian, Keith Malarick, Wayne Matson, and Steven M Hersch. 2015. “A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease.” Annals of Clinical and Translational Neurology 2 (7): 756-768. doi:10.1002/acn3.214. http://dx.doi.org/10.1002/acn3.214.
Full Text & Related Files:
Abstract: Objective: Huntington’s disease (HD) is a rare neurodegenerative disease caused by the expansion of an N-terminal repeat in the huntingtin protein. The protein is expressed in all cells in the body; hence, peripheral tissues, such as blood, may recapitulate processes in the brain. The plasma metabolome may provide a window into active processes that influence brain health and a unique opportunity to noninvasively identify processes that may contribute to neurodegeneration. Alterations in metabolic pathways in brain have been shown to profoundly impact HD. Therefore, identification and quantification of critical metabolomic perturbations could provide novel biomarkers for disease onset and disease progression. Methods: We analyzed the plasma metabolomic profiles from 52 premanifest (PHD), 102 early symptomatic HD, and 140 healthy controls (NC) using liquid chromatography coupled with a highly sensitive electrochemical detection platform. Results: Alterations in tryptophan, tyrosine, purine, and antioxidant pathways were identified, including many related to energetic and oxidative stress and derived from the gut microbiome. Multivariate statistical modeling demonstrated mutually distinct metabolomic profiles, suggesting that the processes that determine onset were likely distinct from those that determine progression. Gut microbiome-derived metabolites particularly differentiated the PHD metabolome, while the symptomatic HD metabolome was increasingly influenced by metabolites that may reflect mutant huntingtin toxicity and neurodegeneration. Interpretation Understanding the complex changes in the delicate balance of the metabolome and the gut microbiome in HD, and how they relate to disease onset, progression, and phenotypic variability in HD are critical questions for future research.
Published Version: doi:10.1002/acn3.214
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531058/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462478
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters